The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.
about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsBeyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint RegulatorsCytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccinesRole of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implicationsA phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinomaTumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates.Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral loadLAG3 expression in active Mycobacterium tuberculosis infectionsExpression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells.LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment.Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression.Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4.Modulation of redox balance leaves murine diabetogenic TH1 T cells "LAG-3-ing" behind.LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer modelLAG-3 in Cancer Immunotherapy.Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Regulatory T cell subsets in filarial infection and their function.Depleting T-cell subpopulations in organ transplantation.Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells.Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: A balance between immunity strength and liver injury extent.The CD4-like molecule LAG-3, biology and therapeutic applications.Emerging immune checkpoints for cancer therapy.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Emerging immunotherapy for the treatment of esophageal cancer.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.LAG3 (CD223) as a cancer immunotherapy target.LAG-3 potentiates the survival of Mycobacterium tuberculosis in host phagocytes by modulating mitochondrial signaling in an in-vitro granuloma model.Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma.Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection.A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy.Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.Control of NK Cell Activation by Immune Checkpoint Molecules.CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer CellsNot All Immune Checkpoints Are Created EqualDescription of CD8 Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and CancerMassive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies
P2860
Q26745842-72D5C19F-751C-4CD6-8408-905F0EB2B45CQ26782799-572BEEF0-0CBE-44F7-BED2-F0D348C312D0Q26827712-56536DB8-670B-45DB-B6DC-7A0DD8956E3EQ27011510-9946B0E8-0F8C-4BDF-B68A-E6B58CFD0435Q30412791-E84A71A9-C2BD-464E-9BCC-DE2A6905C80DQ33842859-14D99586-CB08-49CB-B545-4F8EFA1DF7ACQ34166913-E6C7D529-6B08-4B47-B335-CE56A31740DEQ34381879-671851FF-9CC0-4943-BA67-666B6A082CE8Q34456062-288166E8-F5C6-4B3B-B72B-13D84B677F5EQ34699537-4D5DC4E7-6384-4C67-9DCC-132A163CCE4DQ34700552-CE4392B1-2537-4EC5-A4A4-DEC6D8BF2555Q35096435-3B4054FD-4562-461D-BC96-D0AAFCA7C069Q35487768-88E60801-D0B8-4F10-9AEC-C26028153D02Q35808883-2798E21C-F20C-44FE-A2C2-5C9A3A450832Q36047584-8595BA9A-DB72-4151-BB2E-103A586B5068Q36413772-0C7EC79A-E52D-4B24-AC8C-D6DD43AB92FBQ36416383-5EE929E3-C151-473C-A5FA-B28C2FC4713AQ36738775-00132383-E4BB-4F9A-AD69-C1A040B6B8FCQ37158481-23DE3392-A2CA-43E8-9A66-F2805C24093CQ37205678-1D7F2D06-32E1-4B2C-AAB7-DF54D08ECD9FQ37316082-52E0EBD1-8394-4C61-B9A9-FF966B5502C1Q37363448-54E75147-86FB-42F3-8D25-C896944A6605Q37582541-7673B08C-B0DC-43BC-B2E7-86B8515ED29CQ37818246-0E772F62-3F3C-4758-9942-3F3E4686DEF5Q38584979-0A623153-D8E5-43AD-A32C-ED5A3C328130Q38730989-80DCB527-10CE-481D-81CA-19ED6925695AQ38763851-17AE9218-1981-4625-B336-6C3D8B661B72Q39078341-31E16799-FF4C-48DE-B274-66C972AAC6D4Q39160974-72956D13-2893-41C3-85BF-8E7D01465CA7Q40062766-000AF349-860A-453F-AC05-A20931C8E3D7Q42079188-C66643EA-1F7A-4739-B736-B2E68466A977Q43047846-31435843-892B-4127-AB71-C643B3B3BA2FQ45415273-6BDBF4C9-1E88-4E31-9BDC-2DF02EAAE45AQ46115026-17C431E6-4464-4DEA-8E5C-0FCBD698FF1CQ47128718-5D98DC46-D35B-47F6-8A09-4AC9D542C1FAQ50030507-62A8C073-AB20-4B03-9C40-2369B6F866CBQ56889003-0279D861-317E-4876-947F-A6F4F8F191D2Q56889626-7A492A12-3A23-4918-A90E-2E085804175FQ56890349-5B5D7A00-4B11-4F15-974B-A5E6C45329B5Q58803983-36CF3748-0032-4A92-9622-541BEE7CFD21
P2860
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The negative regulatory functi ...... ptor (CD223) on human T cells.
@ast
The negative regulatory functi ...... ptor (CD223) on human T cells.
@en
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor
@nl
type
label
The negative regulatory functi ...... ptor (CD223) on human T cells.
@ast
The negative regulatory functi ...... ptor (CD223) on human T cells.
@en
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor
@nl
prefLabel
The negative regulatory functi ...... ptor (CD223) on human T cells.
@ast
The negative regulatory functi ...... ptor (CD223) on human T cells.
@en
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor
@nl
P2860
P1433
P1476
The negative regulatory functi ...... ptor (CD223) on human T cells.
@en
P2093
Frédéric Triebel
Laëtitia Maçon-Lemaître
P2860
P304
P356
10.1111/J.1365-2567.2005.02145.X
P577
2005-06-01T00:00:00Z